NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
Clinical Trials
26 trialsNCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT01649778 2020-07-15
PRINCIPAL
Novartis
Completed
NCT02014636 2020-03-03
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
Novartis
Phase 1 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00363194 2017-11-17
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00478725 2017-11-17
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
GlaxoSmithKline
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00401583 2017-11-13
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT01521715 2017-08-23
FLIPPER
iOMEDICO AG
Phase 4 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00256880 2017-01-18
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Completed
NCT00334282 2016-02-05
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
GlaxoSmithKline
Phase 3 Completed
NCT01446224 2015-03-27
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
GlaxoSmithKline
Completed
NCT00387764 2014-01-14
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
GlaxoSmithKline
Phase 3 Completed